Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study

Dig Dis Sci. 2010 Oct;55(10):2887-92. doi: 10.1007/s10620-009-1097-5. Epub 2010 Jan 22.

Abstract

Aims: We aimed to determine differences in gastroduodenal damage related to the presence of Helicobacter pylori (Hp) in patients starting long-term NSAID therapy. Seventy-one candidates for chronic NSAIDs therapy (33 Hp negative and 38 Hp positive) entered the study and underwent upper GI endoscopy before, and 8 and 16 weeks after, continuous NSAID therapy.

Results: Lanza score increased in both Hp positive and negative patients in the course of NSAID therapy (P < 0.001), being significantly higher in Hp positive than Hp negative (4.31 ± 1.33 vs 3.15 ± 1.95, P < 0.05) after 16 weeks of follow-up. In gastric mucosa, no significant difference in mean Lanza score was observed between the two groups. Duodenal ulcer was diagnosed in 18 (36.8%) Hp positive and 1 (3%) Hp negative patient (P < 0.05).

Conclusions: Hp is more closely related to duodenal than gastric mucosal injury in NSAID users. Risk for duodenal ulcer in Hp-infected individual increases after 4 months of NSAID therapy.

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Biopsy
  • Duodenal Ulcer / epidemiology
  • Duodenal Ulcer / microbiology
  • Duodenal Ulcer / pathology
  • Endoscopy, Gastrointestinal
  • Female
  • Follow-Up Studies
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / pathology
  • Gastritis / epidemiology
  • Gastritis / microbiology*
  • Gastritis / pathology*
  • Helicobacter Infections / epidemiology
  • Helicobacter Infections / pathology*
  • Helicobacter pylori*
  • Humans
  • Male
  • Middle Aged
  • Registries
  • Rheumatic Diseases / drug therapy*
  • Rheumatic Diseases / epidemiology
  • Risk Factors
  • Time Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal